Known targets — ChEMBL curated mechanism
PPARDPTGS1PTGS2dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Lysine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 10/20 | 0.50 |
| ▸ | GSR | P00390 | 1/20 | 0.48 |
| ▸ | MME | P08473 | 1/20 | 0.47 |
| ▸ | MMP2 | P08253 | 1/20 | 0.46 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.46 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.46 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.46 |
| ▸ | CPA1 | P15085 | 1/20 | 0.45 |
| ▸ | CPA2 | P48052 | 1/20 | 0.45 |
| ▸ | CPA4 | Q9UI42 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ornithine Aketoglutarate SCHEMBL6417590 | 0.96 | MME (0.48) | ACEMME | |
| SCHEMBL6419023 | 0.91 | GRIK1 (0.52) | ACEMME | |
| Homophenylalanine SCHEMBL6419916 | 0.90 | MME (0.53) | ACEMME | |
| SCHEMBL6412096 | 0.89 | ACE (0.51) | ACEMME | |
| Norleucine SCHEMBL6417632 | 0.89 | ACE (0.53) | ACEMME | |
| D-Glutamate SCHEMBL6418051 | 0.85 | MME (0.49) | ACEGSRMME | |
| Serine SCHEMBL6413334 | 0.85 | MME (0.51) | ACEMME | |
| Dl-Phenylalanine SCHEMBL6415329 | 0.85 | ALPI (0.58) | ACEMME | |
| Alanine SCHEMBL6415193 | 0.85 | MME (0.56) | ACEMME | |
| SCHEMBL3369279 | 0.84 | MME (0.61) | ACEMME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5932551-A | INHIBITORS OF MATRIX METALLOENDOPROTEINASE-MEDIATED DISEASES | MERCK & CO., INC. (US) | 1999-08-03 | — | — | US | claimed |
| EP-0586537-A4 | SUBSTITUTED N-CARBOXYALKYLPEPTIDYL DERIVATIVES AS ANTIDEGENERATIVE ACTIVE AGENTS | MERCK & CO INC (US) | 1997-06-25 | — | — | EP | claimed |
| EP-0586537-A1 | SUBSTITUTED N-CARBOXYALKYLPEPTIDYL DERIVATIVES AS ANTIDEGENERATIVE ACTIVE AGENTS | MERCK & CO. INC. (US) | 1994-03-16 | — | — | EP | claimed |
| WO-1992021360-A1 | SUBSTITUTED N-CARBOXYALKYLPEPTIDYL DERIVATIVES AS ANTIDEGENERATIVE ACTIVE AGENTS | MERCK & CO., INC. (US) | 1992-12-10 | — | — | WO | claimed |
| US-20050020607-A1 | Statin-MMP inhibitor combinations | NEWTON ROGER SCHOFIELD (US) | 2005-01-27 | — | — | US | disclosed |
| EP-1366765-A1 | Use of matrix metalloproteinase inhibitors for treating neurological disorders and promoting wound healing | WARNER-LAMBERT COMPANY LLC (US) | 2003-12-03 | — | — | EP | disclosed |
| EP-1047450-B1 | ACE INHIBITOR-MMP INHIBITOR COMBINATIONS | WARNER LAMBERT CO (US) | 2002-10-02 | — | — | EP | disclosed |
| US-20020049237-A1 | Statin-MMP inhibitor combinations | NEWTON ROGER SCHOFIELD (US) | 2002-04-25 | — | — | US | disclosed |
| US-6340709-B1 | ADMINISTERING BIPHENYLSULFONAMIDE DERIVATIVE | WARNER-LAMBERT COMPANY | 2002-01-22 | — | — | US | disclosed |
| US-6133304-A | TREATING FIBROSIS, VENTRICULAR DILATION, AND/OR HEART FAILURE IN A MAMMAL BY ADMINISTERING AN ANTIFIBROTIC AMOUNT OF A MIXTURE OF AN ANGIOTENSIN-CONVERTING ENZYME(ACE) INHIBITOR AND AT LEAST ONE MATRIX METALLOPROTEINASE(MMP) INHIBITOR | WARNER-LAMBERT COMPANY (US) | 2000-10-17 | — | — | US | disclosed |
| EP-1028716-A1 | METHOD FOR TREATING AND PREVENTING HEART FAILURE AND VENTRICULAR DILATATION | WARNER-LAMBERT COMPANY (US) | 2000-08-23 | — | — | EP | disclosed |
| US-5948780-A | ADMINISTERING A METALLOPROTEINASE INHIBITOR | WARNER-LAMBERT COMPANY (US) | 1999-09-07 | — | — | US | disclosed |
| US-5932551-A | INHIBITORS OF MATRIX METALLOENDOPROTEINASE-MEDIATED DISEASES | MERCK & CO., INC. (US) | 1999-08-03 | — | — | US | disclosed |
| WO-1998025597-A2 | METHOD FOR TREATING AND PREVENTING HEART FAILURE AND VENTRICULAR DILATATION | WARNER-LAMBERT COMPANY (US) | 1998-06-18 | — | — | WO | disclosed |
| EP-0586537-A4 | SUBSTITUTED N-CARBOXYALKYLPEPTIDYL DERIVATIVES AS ANTIDEGENERATIVE ACTIVE AGENTS | MERCK & CO INC (US) | 1997-06-25 | — | — | EP | disclosed |
| EP-0586537-A1 | SUBSTITUTED N-CARBOXYALKYLPEPTIDYL DERIVATIVES AS ANTIDEGENERATIVE ACTIVE AGENTS | MERCK & CO. INC. (US) | 1994-03-16 | — | — | EP | disclosed |
| WO-1992021360-A1 | SUBSTITUTED N-CARBOXYALKYLPEPTIDYL DERIVATIVES AS ANTIDEGENERATIVE ACTIVE AGENTS | MERCK & CO., INC. (US) | 1992-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020607-A1 | Statin-MMP inhibitor combinations | MMP9, TIMP3, MMP3 | ACE 52/4885GSR 1270/4885MME 174/4885 |
| US-20020049237-A1 | Statin-MMP inhibitor combinations | MMP9, TIMP3, MMP3 | ACE 52/4885GSR 1270/4885MME 174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.